Insider Buying: OraSure Technologies (NASDAQ:OSUR) Director Acquires $74,500.00 in Stock

OraSure Technologies, Inc. (NASDAQ:OSUR) Director Steven Kyle Boyd bought 25,000 shares of OraSure Technologies stock in a transaction on Tuesday, May 12th. The stock was acquired at an average cost of $2.98 per share, for a total transaction of $74,500.00. Following the acquisition, the director owned 63,462 shares in the company, valued at approximately $189,116.76. This represents a 65.00% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Steven Kyle Boyd also recently made the following trade(s):

• On Thursday, May 14th, Steven Kyle Boyd bought 25,000 shares of OraSure Technologies stock. The stock was acquired at an average cost of $2.99 per share, for a total transaction of $74,750.00.

OraSure Technologies Stock Performance

Shares of OSUR stock opened at $3.00 on Friday. The stock’s fifty day moving average price is $3.06 and its two-hundred day moving average price is $2.76. The company has a market cap of $206.55 million, a PE ratio of -2.88 and a beta of 0.89. OraSure Technologies, Inc. has a fifty-two week low of $2.08 and a fifty-two week high of $3.82.

OraSure Technologies (NASDAQ:OSUR) last issued its earnings results on Wednesday, February 25th. The medical instruments supplier reported ($0.19) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.02). The business had revenue of $26.76 million during the quarter, compared to analyst estimates of $26.44 million. OraSure Technologies had a negative net margin of 66.42% and a negative return on equity of 18.57%.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of OSUR. Amundi acquired a new position in OraSure Technologies during the 1st quarter worth about $47,000. AQR Capital Management LLC lifted its holdings in OraSure Technologies by 48.3% during the 1st quarter. AQR Capital Management LLC now owns 1,041,875 shares of the medical instruments supplier’s stock worth $3,511,000 after buying an additional 339,493 shares during the period. NewEdge Advisors LLC lifted its holdings in OraSure Technologies by 32,595.9% during the 1st quarter. NewEdge Advisors LLC now owns 47,736 shares of the medical instruments supplier’s stock worth $161,000 after buying an additional 47,590 shares during the period. Empowered Funds LLC lifted its holdings in OraSure Technologies by 7.2% during the 1st quarter. Empowered Funds LLC now owns 405,216 shares of the medical instruments supplier’s stock worth $1,366,000 after buying an additional 27,310 shares during the period. Finally, Envestnet Asset Management Inc. lifted its holdings in OraSure Technologies by 32.7% during the 2nd quarter. Envestnet Asset Management Inc. now owns 33,018 shares of the medical instruments supplier’s stock worth $99,000 after buying an additional 8,133 shares during the period. 93.50% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Separately, Weiss Ratings raised OraSure Technologies from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, May 7th. Two investment analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Reduce” and an average price target of $3.00.

About OraSure Technologies

OraSure Technologies, Inc is a Bethlehem, Pennsylvania–based diagnostic and medical device company specializing in the development, manufacture and commercialization of point-of-care and self-testing products. Founded in 1988, OraSure has built a portfolio of oral fluid and other non-invasive specimen collection technologies that support the detection of infectious diseases, drugs of abuse, and health and wellness biomarkers.

The company’s flagship product, the OraQuick® rapid HIV test, was the first Food and Drug Administration–approved over-the-counter oral fluid test for the detection of HIV-1/2 antibodies.